SEC Form 4 · accession 0001424422-17-000011
BioPharmX Corp · BPMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Morlock
Director
Period of report
Nov 24, 2017
Accepted (ET)
Nov 27, 2017 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001504167
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Nov 24, 2017 | P | 330,000 | $0.15 | A | 873,956 | D | |
| Common stockF2 | holding | — | — | — | 251,071 | I | By Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to purchase common stockF1,F3 | $0.20 | Nov 24, 2017 | P | 330,000 | A | — | — | Common stock | 330,000 | 330,000 | D |
| Warrant to purchase common stockF1,F4 | $0.25 | Nov 24, 2017 | P | 330,000 | A | — | — | Common stock | 330,000 | 330,000 | D |
Explanation of responses
- F1Securities are purchased as a unit, priced at $0.15 per unit, which consists of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock.
- F2Mr. Morlock is a co-trustee and co-beneficiary of the Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03
- F3This Series A warrant is immediately exercisable and expires on 11/24/2022.
- F4This Series B warrant is immediately exercisable and expires on the earlier of (1) the 21st trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its phase 3 trials for BPX01 and (2) the 18 month anniversary of issuance.